Drug Industry – Talk Bio

Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation

6 days ago talkbio0Tagged Capitalization, Drug Industry, eli lilly, Glucagon-Like Peptide 1, Market, Mounjaro, valuation, Weight-Loss Agents, Zepbound

Eli Lilly; trillion-dollar valuation; weight-loss drugs; Mounjaro; Zepbound; GLP-1 market; pharmaceutical industry; stock market; market capitalization

Novartis Raises Sales Targets for Key Cancer Drugs, Tweaks Yearly Growth Guidance

1 week ago talkbio0Tagged cancer drugs, Drug Industry, Kisqali, leukemia, Malignant neoplasm of breast, Novartis, peak sales, Pluvicto, sales guidance, Scemblix

Novartis; Kisqali; Scemblix; Pluvicto; sales guidance; peak sales forecast; cancer drugs; breast cancer; leukemia; pharmaceutical industry

Pfizer Triumphs Over Novo Nordisk with $10B Bid to Acquire Metsera

3 weeks ago talkbio0Tagged Acquisition, Approved, bidding war, Drug Industry, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, shareholder

Pfizer; Novo Nordisk; Metsera; obesity drugs; GLP-1; acquisition; bidding war; shareholder approval; pharmaceutical industry

Novo Nordisk Ups the Stakes With $10B Bid for Metsera, Surpassing Pfizer’s Offer

3 weeks ago talkbio0Tagged antitrust litigation, bidding war, contingent value right, Drug Industry, Metsera, Novo Nordisk, Pfizer

Novo Nordisk; Pfizer; Metsera; bidding war; acquisition; $10 billion; contingent value right; pharmaceutical industry; antitrust litigation

Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer

3 weeks ago talkbio0Tagged Cancer Therapeutic Procedure, Chief Strategy Officer, Drug Industry, Marcel Reichen, Neoplasms, Precision - temporal, radioligand therapy, Radiopharmaceuticals, Ratio Therapeutics, Strategic Growth

Ratio Therapeutics; Marcel Reichen; Chief Strategy Officer; radiopharmaceuticals; oncology; radioligand therapy; pharmaceutical industry; cancer treatment; strategic growth; precision oncology

Astellas Pharma Revises Financial Forecasts for FY2025

4 weeks ago talkbio0Tagged Astellas, Drug Industry, Financial Forecast Revision, FY2025, operating profit, Optimization, Pipeline Progress, Revenue Upgrade, SG&A, strategic brands

Astellas; Financial Forecast Revision; FY2025; Revenue Upgrade; Operating Profit; Pharmaceutical Industry; Strategic Brands; Pipeline Progress; SG&A Optimization

Vistagen Appoints Paul Edick to its Board of Directors

4 weeks ago talkbio0Tagged Audit Committee, Biological Factors, board of directors, Compensation Committee, Corporate governance, Drug Industry, Paul Edick, Vistagen

Vistagen; Paul Edick; Board of Directors; Audit Committee; Compensation Committee; Biopharmaceutical; Pharmaceutical industry; Corporate governance

Eli Lilly and Nvidia to Build Pharma’s Largest AI Supercomputer for Drug Discovery

4 weeks ago talkbio0Tagged Artificial Intelligence, biomedical foundation models, Blackwell Ultra GPU, Clinical Trials, Drug Discovery, Drug Industry, eli lilly, high-performance computing, NVIDIA, supercomputer

Eli Lilly; Nvidia; supercomputer; AI; drug discovery; Blackwell Ultra GPU; clinical trials; biomedical foundation models; pharmaceutical industry; high-performance computing

Cuts Continue as Novo Nordisk Restructuring Moves Forward

1 month ago talkbio0Tagged Drug Industry, Novo Nordisk, restructuring

Novo Nordisk; Restructuring; Job Cuts; Pharmaceutical Industry

BioCryst Snaps Up Fellow Angioedema Player Astria for $700M

1 month ago talkbio0Tagged Acquisition, Angioedemas, Hereditary, Astria, BioCryst, Cash, Drug Industry, navenibart, Rare Diseases

BioCryst; Astria Therapeutics; acquisition; hereditary angioedema (HAE); navenibart; rare disease; pharmaceutical industry; cash and stock deal; Jill Milne; $700 million